EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Histopathologic and Molecular Insights Following the Management of Ameloblastomas via Targeted Therapies – Pathological and Clinical Perspectives

Ariel Hirschhorn, Shirly Grynberg, Gadi Abebe Campino, Alex Dobriyan, Vinod Patel, Gahl Greenberg, Rinat Yacobi, Iris Barshack, Ran Yahalom, Amos Toren, Marilena Vered

Head and Neck Pathology · 2024

DOI: 10.1007/s12105-024-01734-2 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Head and Neck Pathology, 2024. Verfasst von Ariel Hirschhorn und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cranio-Maxillofacial Surgery, Chaim Sheba Medical Center, Tel Hashomer, Israel. Hauptthemen laut MEDLINE: Ameloblastoma, Jaw Neoplasms. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Tel Aviv University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

Current standard of care for ameloblastoma (conventional/unicystic - mural type) usually mandates extensive bone resection that frequently necessitates immediate reconstruction with serious sequelae, especially among young patients. BRAF -mutated ameloblastomas can be targeted by BRAF inhibitors to markedly reduce their size, enabling conservative removal of residual tumor. We aimed to characterize the effect of post-treatment histomorphologic changes.

Methods

Study included 14 patients, 11 mandibular and three maxillary tumors. Cases with very minimal residual tumor were defined as near-complete response, while those with mostly vital residual tumor as partial response. The epithelium component was scored for architectural and cellular changes, stroma - for fibrosis, inflammation and new bone formation, on a 3-tired score system: 0–no, 1–focal and 3–frequent changes. The mean scores of each parameter, total epithelium and total stroma were calculated and related to duration of treatment. Differences in the mean scores were investigated for mandibular tumors with near-complete response ( n = 3) and partial response ( n = 8).

Results

There were no significant differences in mean epithelium or stroma scores between tumors with near-complete and those with partial response (2.22 ± 0.68 versus 2.08 ± 0.43, p = 0.55; 1.41 ± 1.04 versus 1.43 ± 0.44, p = 0.27), suggesting that ameloblastomas have potential to undergo complete response to targeted treatment. This is probably dependent upon tumor/patient/treatment-related factors. Response to treatment appears to be predictable with neoplastic epithelium being first, while the stromal response increases during treatment, the entire process expanding over weeks-to-months.

Conclusion

Albeit preliminary, these are the first comprehensive histomorphologic findings on BRAF-treated ameloblastomas. Analyzing the suggested parameters in tumors with partial response, should highlight which tumor component has responded/failed to respond. This could serve as a basis for decision-taking toward subsequent steps in adjuvant treatment (e.g., follow-up, conservative surgery, modifications/changes in treatment regimen, combinations of approaches), with a prime aim of jaw preservation and minimal risk of sequelae.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AmeloblastomaJaw NeoplasmsHumansMaleFemaleAdultMiddle AgedYoung AdultAdolescentProto-Oncogene Proteins B-rafAgedMolecular Targeted Therapy

Stichwörter der Autor:innen

AmeloblastomaBRAF mutationEpitheliumResponseStromaTargeted therapy

Substanzen

Proto-Oncogene Proteins B-rafBRAF protein, human

Autor:innen und Institutionen

  • Department of Cranio-Maxillofacial Surgery, Chaim Sheba Medical Center, Tel Hashomer, Israel.
  • Ella Lemelbaum Institute for Immuno-Oncology, and Melanoma, Chaim Sheba Medical Center, Tel Hashomer, Israel.
  • Division of Pediatric Hemato-Oncology, Edmond and Lily Safra Children's Hospital, Sheba Medical Center, Tel Hashomer, Israel.
  • Department of Oral Surgery, Guys & St Thomas Hospital, London Bridge, London, UK.
  • Department of Diagnostic Imaging, Sheba Medical Center, Tel Hashomer, Israel.
  • Institute of Pathology, Sheba Medical Center, Tel Hashomer, 5265601, Israel.

Förderung

  • Tel Aviv University

Zitieren

APA

Hirschhorn, A., Grynberg, S., Campino, G. A., Dobriyan, A., Patel, V., Greenberg, G., Yacobi, R., Barshack, I., Yahalom, R., Toren, A., & Vered, M. (2024). Histopathologic and Molecular Insights Following the Management of Ameloblastomas via Targeted Therapies – Pathological and Clinical Perspectives. Head and Neck Pathology. https://doi.org/10.1007/s12105-024-01734-2

Vancouver

Hirschhorn A, Grynberg S, Campino GA, Dobriyan A, Patel V, Greenberg G, et al. Histopathologic and Molecular Insights Following the Management of Ameloblastomas via Targeted Therapies – Pathological and Clinical Perspectives. Head and Neck Pathology. 2024. doi:10.1007/s12105-024-01734-2

BibTeX
@article{Hirschhorn2024,
  author = {Hirschhorn, Ariel and Grynberg, Shirly and Campino, Gadi Abebe and Dobriyan, Alex and Patel, Vinod and Greenberg, Gahl and Yacobi, Rinat and Barshack, Iris and Yahalom, Ran and Toren, Amos and Vered, Marilena},
  title = {Histopathologic and Molecular Insights Following the Management of Ameloblastomas via Targeted Therapies – Pathological and Clinical Perspectives},
  journal = {Head and Neck Pathology},
  year = {2024},
  doi = {10.1007/s12105-024-01734-2}
}
Kostenlos starten →